Antitumor immunity: Easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5613-5617

  Maher, John ^a,b,c   Adami, Antonella A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC T CELL ENGAGER ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; CD3 ANTIGEN; CETUXIMAB; EPITHELIAL CELL ADHESION MOLECULE; FC RECEPTOR; MONOCLONAL ANTIBODY; OXALIPLATIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DEATH; CELL SURFACE; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MALIGNANT ASCITES; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; SIDE EFFECT; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 84884737325     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1852     Document Type: Review

References (30)

1. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012;18:3478-86.
2. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother 2011;60:1061-74.
3. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
5. Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012;2012: 278093.
6. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
7. Riethmuller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012;12:12.
8. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995;92: 7021-5.
9. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 2008;321:974-7.
10. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8.
11. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 2013;121:5154-7.
12. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17:385-92.
13. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52.
14. Kurtz JE, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther 2010;10:951-8.
15. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209-21.
16. Jager M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti- EpCAM x anti-CD3). Cancer Res 2012;72:24-32.
17. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
18. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34.
19. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012;72:3958-66.
20. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential speciesrestricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-25.
21. Goere D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, et al. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. Cancer Res 2013;73:4663-73.
22. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30: 61-9.
23. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010;59:1197-209.
24. Ott MG,Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-203.
25. Pietzner K, Vergote I, Santoro A, Marme F, Rosenberg P, Friccus- Queke H, et al. Results of a phase II clinical trial to evaluate a rechallenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). J Clin Oncol 31, 2013 (suppl; abstr 5582).
26. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009;28:18.
27. Wimberger P, Heubner M, Lindhofer H, Jager M, Kimmig R, Kasimir- Bauer S. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res 2009;29:1787-91.
28. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012;29:3416-20.
29. Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol. 2012. [Epub ahead of print].
30. Russel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, et al. Inflammatory lesions of the peritoneummimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. J Clin Oncol 2011;29:e644-6.